# Imetelstat Combinations in Relapsed AML

> **NCT07320235** · PHASE1 · RECRUITING · sponsor: **Douglas Tremblay** · enrollment: 36 (estimated)

## Conditions studied

- Relapsed Acute Myeloid Leukemia

## Interventions

- **DRUG:** Imetelstat
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07320235
- **Lead sponsor:** Douglas Tremblay
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-02
- **Primary completion:** 2030-06-17
- **Final completion:** 2035-06-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- Geron Corporation

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07320235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07320235, "Imetelstat Combinations in Relapsed AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07320235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*